Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023
August 05, 2022 at 03:00 am EDT
Share
Kissei Pharmaceutical Co., Ltd. provided earning guidance for the first half ending September 30, 2022 and full year ending March 31, 2023. For the first half ending September 30, 2022, the company expects net sales of JPY 31,000 million, operating loss of JPY 1, 300 million, ordinary loss of JPY 500 million, profit attributable to owners of parent of JPY 3,000 million and basic earnings per share of JPY 65.05 per share.
For the full year ending March 31, 2022, the company expects net sales of JPY 68,000 million, operating profit of JPY 2,800 million, ordinary profit of JPY 4,400 million, profit attributable to owners of parent of JPY 10,000 million and basic earnings per share of JPY 216.85 per share.
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
KISSEI PHARMACEUTICAL CO., LTD. 
